Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., March 31, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that company management will participate virtually in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 12:45 p.m. ET.
A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.
About Blueprint Medicines
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit www.BlueprintMedicines.com and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.
View original content to download multimedia: https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-24th-annual-needham-virtual-healthcare-conference-302411391.html
SOURCE Blueprint Medicines Corporation
